Rhone-Alpes Creation
10, rue du Chateau d'Eau, Lyon, Rhône-Alpes, 69410, France
Overview
Rhone-Alpes Creation is a venture capital firm that focuses on early-stage investments in software and biotechnology.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- NightSwapping
Participated · Equity · Sep 2014
NightSwapping operates a peer-to-peer home‑swap platform where members host guests and earn "nights" to stay at other private locations. The company offers protections covering potential property damage and physical injuries. It reports a community of 180k members across 160 countries. Led by founder and CEO Serge Duriavig, NightSwapping plans to use new capital to expand operations in Europe and the Americas. Financially, the company has raised approximately €4m to date, including the recent second round. The platform is positioned to grow its user base and geographic reach with the additional funding. Cosmopolit Home operates a peer-to-peer nights exchange platform based on the nightswapping concept, allowing private individuals to experience free stays regardless of length or destination. The service has attracted a community of about 6,000 hosts across 54 countries. Founded by Serge Duriavig, the company is based in Lyon, France. Cosmopolit Home intends to use its recent funding to expand operations into Europe and across the Atlantic. Financially, the company completed a €2m fundraise to support that expansion. No additional revenue or user-monetization details are provided in the article.
- Synthelis
Participated · Equity · Jan 2014
Synthelis Biotech is an Isère-based startup focused on acellular (cell-free) manufacturing of complex proteins intended for therapeutic drugs and vaccines. Its proprietary technology aims to streamline and scale the production of proteins that are typically difficult to express with traditional cell-based systems. By eliminating living cells from the process, the company targets faster development cycles and greater control over product quality. The firm plans to move from laboratory-scale proof-of-concept to industrial-scale manufacturing. Recent state backing is intended to accelerate this industrialization phase. Although specific revenue, customer, or production metrics were not disclosed, the new support underlines the company’s transition from R&D to commercialization. Future efforts will likely focus on building production capacity and forging partnerships with biotech and pharmaceutical clients.
Team
No current team members are available.